Announced Date: 2025-11-03 (November 3, 2025)
Licensor (Seller): TransThera Sciences (China)
Licensee (Buyer): Neurocrine Biosciences (US)
.
Asset Name: NLRP3 Program
Asset Modality: Small Molecule
Asset Target: NLRP3 Inhibitor
Potential Indication:
Current Stage:
.
Scope of Authority:
Neurocrine Biosciences will obtain exclusive rights to develop, manufacture and commercialize the NLRP3 program out of Great China.
.
Payment Detail:
Detail Undisclosed.
TransThera Sciences will receive an upfront payment, development and sales milestone payments, total up to 881.5 USD million and royalties based on sales revenue from Taiho.
.
Link:
20251103378892.pdf (xueqiu.com)
.
Note:
Chinese Name of TransThera Sciences 药捷安康
